Blood substitute nLiven PRhPL for stem cell culture

Sexton peopleBlood substitute nLiven PRhPL for stem cell culture(Platelet lysate, serum replacement)

Sexton in the United States has no animal sources and does not require the addition of heparinBlood substitute nLiven PRhPL for stem cell culture(Platelet lysate) has been reported in hundreds of literature as a good cell culture supplement for mesenchymal stem cells (MSCs) and CAR-T/NK cell expansion using platelet lysate from Sexton Corporation in the United States. Based on user research, clinical, and GMP production needs, clinical or research grade formulations are provided, while meeting quality and regulatory requirements. The drug master file BMF has been filed with the FDA and is used as a higher performance FBS substitute in clinical stem cell and immune oncology applications worldwide. The main features are as follows:

·Compatibility: As a culture medium supplement, FBS fetal bovine serum substitute or AB serum substitute is suitable for the cultivation of various cell types including MSCs, T cells, NK cells, endothelial cells, etc.

·Safety: The reduction of pathogens has been verified, and sterile, mycoplasma, and endotoxin tests have been conducted.

·Reproducibility: By gathering over 100 American human donors from AABB certified/FDA registered blood centers, batch to batch differences were reduced.

·Reliability: AABB certification/FDA registration certification blood source.

·Compliance: Produced in the environment required by Chapter 5.2.12.4 of the European Pharmacopoeia and certified by FDA BMF.

·No need for heparin: The production and use of the product do not require the addition of heparin.

·Easy to use: Add to the culture medium in proportion, with optional sizes of 100ml and 500ml.

·Stable supply: Long term domestic spot goods to meet clinical and large-scale commercial production needs.

The main features of nLevin are as follows:

Suitable for immune cell culture such as CAR-T/NK

• No animal derived ingredients

FDA Biological Products Master File BMF Filing

100 clinical projects in progress

No need for heparin, it can replace serum and be added to the culture medium for use

• hPL supply from early development to clinical and commercial production